SIGLEC14 encodes a sialic acid-binding immunoglobulin-like lectin that functions as an activating receptor on immune cells, particularly monocytes and granulocytes 1. Unlike its inhibitory counterpart Siglec-5, Siglec-14 associates with DAP12 and promotes immune activation through positive signaling 2. The protein enhances NLRP3 inflammasome activation in macrophages, leading to increased IL-1β secretion and caspase-1 activation in response to bacterial pathogens like group B Streptococcus 3. SIGLEC14 serves as a high-affinity receptor for Neisseria meningitidis adhesin A (NadA), facilitating bacterial adhesion and invasion 4. A common deletion polymorphism creates a SIGLEC14 null allele found across human populations, with higher frequency in Asians, which affects immune responses to pathogens including Mycobacterium tuberculosis 15. The null allele is associated with protection from tuberculosis meningitis and altered cytokine responses to BCG vaccination 5. Recent studies suggest SIGLEC14 may have broader roles in cancer susceptibility and could serve as a potential therapeutic target 6.